INTRODUCTION {#S1}
============

Developmental hematopoiesis is composed of temporally orchestrated programs that generate both the differentiated blood cells to support embryonic growth and the undifferentiated hematopoietic stem cells (HSCs) to sustain post-natal hematopoiesis. This challenge is met by segregating hematopoiesis into multiple waves that occur in different anatomical locations. The earliest ("primitive") hematopoietic wave starts in the extra-embryonic yolk sac (YS) at embryonic day (E) 7.5 and gives rise to erythroid cells that fulfill the immediate metabolic needs of the embryo (EM) ([@R33]). They are characterized by the expression of embryonic β globin (betaH1 in mice) ([@R18]). At E8.5--9.5, the YS also generates an intermediate ("transient-definitive") wave of erythro-myeloid progenitors (EMPs) ([@R27]; [@R30]; [@R39]) that produce red cells expressing "definitive" adult type β globins (beta-major in mice) ([@R25]). However, YS EMPs lack self-renewal ability and lymphoid potential, the hallmarks of HSCs. It has been proposed that EMPs initiate fetal liver (FL) definitive hematopoiesis and play roles in supporting embryonic survival ([@R7]), inflammatory signaling during HSC emergence ([@R9]), and adult tissue-resident macrophage development ([@R15]). However, the duration and significance of this intermediate hematopoietic wave are not fully understood.

The final ("definitive") wave generates self-renewing, multipotent HSCs that sustain lifelong production of all blood cell types. Transplantable HSCs are first identified at E10.5--11.5 in the intra-embryonic para-aortic splanchnopleural/aorta-gonad-mesonephros region (pSP/AGM) and the vitelline and umbilical vessels that connect the pSP/AGM to extra-embryonic tissues ([@R29]; [@R35]). Several studies suggest that the YS and the placenta (PL) can also generate multipotent hematopoietic stem and progenitor cells (HSPCs) de novo ([@R19]; [@R45]; [@R46]; [@R55], [@R56]; [@R58]). Observations from direct transplantation of pre-circulation YS into congenic embryos and inducible *Runx1* lineage-tracing studies supported the hypothesis that YS contributes to adult hematopoiesis ([@R46]; [@R55], [@R56]). Furthermore, in vitro experiments with placental tissues isolated before or without the onset of blood circulation demonstrated multi-lineage hematopoietic potential ([@R45]; [@R58]). However, the degree to which each organ contributes to the post-natal HSC pool is unknown.

Lineage tracing and time-lapsed imaging of HSPC emergence in vitro and in vivo evidenced that definitive HSPCs arise from specialized endothelial cells, named hemogenic endothelium ([@R4]; [@R5]; [@R6]; [@R8]; [@R24]; [@R59]). Hemogenic competence in the endothelium is established by the stem cell leukemia gene/T cell acute leukemia gene 1 (*Scl*/*Tal1*), which activates a broad transcriptional network of hematopoietic regulators and prevents misspecification of the endothelium to cardiac fate ([@R53]). SCL activates RUNX1 and other transcription factors that enable HSPC emergence from hemogenic endothelium ([@R38]). SCL is also essential for the generation of primitive erythroid cells and controls the terminal maturation of erythroid cells at all stages of ontogeny ([@R31]; [@R47]; [@R49]). The identity of the precursors for the primitive erythroid cells and the timing when they diverge from the definitive hematopoietic lineages are not known. The presumption that primitive and definitive hematopoietic waves represent distinct lineages that arise from their own precursors ("lineage switch" model) has been challenged by studies that show sequential expression of both the primitive and definitive globins ("maturational switch" model) during erythroid maturation ([@R21]; [@R26]; [@R40];[@R44]).

Although the fundamentals of the developmental hematopoietic hierarchy are gradually being revealed, the contributions of each wave and hemogenic tissue to fetal and post-natal hematopoiesis remain poorly defined because of the lack of wave- and tissue-specific tools that would enable prospective isolation and tracking of the progeny of the temporally and spatially overlapping blood precursors. Most surface antigens expressed in the hemogenic endothelium or emerging HSPCs--e.g., *Flk1, CD31*, *VE-Cadherin, Tie2, CD41*, *ckit*, and *Sca1*--are developmentally regulated but not specific to any individual wave or anatomical site ([@R28]; [@R30]). The use of inducible lineage-tracing studies using regulatory elements of hematopoietic transcription factors (e.g., *Runx1)* is complicated by the fact that the expression of such factors is not restricted to a particular hemogenic tissue ([@R46]). Thus, there are no robust methods to separate or genetically target in vivo individual hematopoietic waves or hemogenic tissues.

Here, we identify the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) as a marker that is differentially and highly expressed in YS endothelium during HSPC development. Lineage tracing by reporter gene expression and conditional deletion of the hematopoietic regulators *Scl* and *Runx1* by *Lyve1-Cre* distinguished YS endothelium, EMPs, and definitive HSPCs from the primitive erythroid lineage. Our data suggest that *Lyve1-Cre-*labeled cells primarily originate from the YS and/or vitelline vessels and contribute to 35%--40% of fetal and adult HSC compartments. At E11.5, the FL pro-erythroblast pool is dominated by LYVE1-lineage cells, whereas by late gestation, the level of marking is similar to the HSC compartment, implying a temporal switch in the composition of precursors responsible for FL erythropoiesis. *Lyve1-Cre* thus provides a unique tool to investigate the contribution of YS hemogenic endothelium to fetal and adult hematopoiesis and the factors that regulate the fate of these cells.

RESULTS {#S2}
=======

LYVE1 Protein Is Expressed in YS Endothelium and Definitive Hematopoietic Cells {#S3}
-------------------------------------------------------------------------------

To define the precursors and respective contributions of the different waves to fetal and adult hematopoiesis, we sought for cell surface markers expressed in hemogenic endothelium that are tissue or wave specific. From a list of genes encoding surface proteins highly expressed in YS endothelium ([@R53]), *Lyve1* emerged as a promising candidate. Initially reported as a marker for lymphatic vessels, LYVE1 expression was later documented also in mid-gestation YS vasculature, FL sinusoids, intersomitic vessels, and the cardinal vein, while being minimal in the dorsal aorta (DA) ([@R1]; [@R16]).

Because LYVE1 expression has not been assessed in the context of developmental hematopoiesis, LYVE1 protein expression was surveyed in hemogenic organs by immunostaining and flow cytometry (FACS). Immunofluorescence (IF) at E10.5 demonstrated robust LYVE1 protein expression in YS and vitelline vasculature, whereas no signal was observed in the PL, umbilical vessels, and DA ([Figure 1A](#F1){ref-type="fig"}). As reported previously, LYVE1 was also expressed in the cardinal vein at E10.5. At E9.5, LYVE1 protein expression in CD31^+^ endothelial cells was ubiquitous in the YS, but minimal in the EM and PL ([Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}). Scant LYVE1 protein was discernible in PL vasculature during HSPC emergence (E11.5) and expansion/maturation (E13.5); however, some LYVE1 protein could be detected at late gestation (E16.5) when the PL HSC pool has already diminished ([@R14]) ([Figure S1A](#SD1){ref-type="supplementary-material"}). At E13.5, LYVE1 expression was also abundant in FL sinusoids and the azygous vein -- tissues incapable of de novo HSPC generation--but not the aorta ([Figure S1B](#SD1){ref-type="supplementary-material"}).

Analysis of the early concepti revealed LYVE1 expression in Tie2^+^CD31^+^ angioblasts already by E7.5 ([Figure S1C](#SD1){ref-type="supplementary-material"}). At E8.5, LYVE1 was present in YS Tie2^+^CD31^+^ angioblasts, but excluded from Ter119^+^ primitive erythroid cells ([Figure S1C](#SD1){ref-type="supplementary-material"}), the embryo, and allantois (data not shown). These data identify the YS and the vitelline vessels as the primary sites harboring LYVE1-expressing endothelium during HSPC emergence. Moreover, these data imply that LYVE1 protein is already expressed in the YS at the time when primitive hematopoiesis begins and the endothelium that gives rise to YS definitive lineages is specified.

We next assessed the expression of LYVE1 protein in YS hematopoietic cells. IF and FACS analyses showed that Ter119^+^ primitive erythroid cells were devoid of LYVE1 expression ([Figures 1D](#F1){ref-type="fig"}, [1E](#F1){ref-type="fig"}, and [1I](#F1){ref-type="fig"}). In contrast, LYVE1 expression was observed in 47.0% ± 19.1% SD of E9.25--9.5 YS CD41^mid^cKit^+^Ter119^−^ HSPC population ([Figures 1F](#F1){ref-type="fig"}, [1G](#F1){ref-type="fig"}, and [1I](#F1){ref-type="fig"}), which consists predominantly of EMPs ([@R10]; [@R32]). Co-staining for the EMP marker CD16/32 ([@R27]) suggested that most LYVE1^+^ HSPCs in E9.25 YS are EMPs ([Figure 1G](#F1){ref-type="fig"}). In contrast to YS HSPCs and EMPs, the E13.5 FL LSK (Lin^−^Sca1^+^cKit^+^) CD150^+^ HSC subset showed minimal LYVE1 expression ([Figures 1H](#F1){ref-type="fig"} and [1I](#F1){ref-type="fig"}).

To assess the origin of LYVE1^+^ HSPCs, LYVE1 expression was examined in concepti that were devoid of blood circulation due to a defective sodium calcium exchanger (Ncx1) required for cardiac activity ([@R23]). FACS analysis of *Ncx1*^−/−^ tissues showed that LYVE1 expression was robust in CD41^mid^cKit^+^ HSPCs in the YS, but minimal in the PL or EM ([Figures 1J](#F1){ref-type="fig"} and [1K](#F1){ref-type="fig"}). Comparable results were observed with CD16/32^+^CD41^mid^cKit^+^ EMPs ([Figure S1D](#SD1){ref-type="supplementary-material"}). These data suggest that the YS is the primary source of LYVE1^+^-expressing HSPCs, including EMPs, in mid-gestation concepti.

*Lyve1-Cre* Labels YS Endothelium and Vitelline Vessels {#S4}
-------------------------------------------------------

To define the contribution of LYVE1^+^ candidate hemogenic endothelial cells to fetal and adult hematopoiesis, lineage tracing was performed by breeding *Lyve1-eGFP-hCre* knockin mice ([@R42]) (referred as *"Lyve1-Cre"* hereafter) with reporter mouse lines. As originally reported, endogenous eGFP signal from the *Lyve1-Cre* line was weak and did not interfere with the signal from the reporter GFP. We first used *Rosa*^*mT*/*mG*^ fluorescent reporter mice ([Figure 2A](#F2){ref-type="fig"}), in which all cells of the conceptus initially express tdTomato. Upon activation of Cre re-combinase, the floxed membrane-targeted tdTomato cassette is excised, allowing the expression of the downstream membrane-targeted EGFP in Cre-expressing cells and their progeny ([@R36]). Maternal blood cells in the PL could be separated from the cells of the conceptus because they were devoid of any fluorescence.

Analysis of *Lyve1-Cre;Rosa*^*mT*/*mG*^ concepti by fluorescence microscopy demonstrated *Lyve1-Cre* labeling already in E8.5 YS ([Figure 2B](#F2){ref-type="fig"}). By E10.5, marking was apparent in YS and vitelline vessels as well as the FL ([Figures 2Ci](#F2){ref-type="fig"}, [2Ciii](#F2){ref-type="fig"}, and [2Civ](#F2){ref-type="fig"}), but absent from umbilical and placental large vessels ([Figure 2Cii](#F2){ref-type="fig"}). In contrast to the robust labeling of CD31^+^ YS and vitelline vessels, the dorsal aorta showed minimal *Lyve1-Cre* labeling ([Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}).

FACS analysis of hemogenic tissues from *Lyve1-Cre; Rosa*^*mT*/*mG*^ concepti at E9.5--E11.5 further documented that VE-Cad^+^CD31^+^ endothelial cells were GFP labeled abundantly in the YS but minimally in the PL and EM (the latter includes the caudal half at E9.5 and the aorta-gonad-mesonephros region at later ages) ([Figures 2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). These data raised the hypothesis that *Lyve1-Cre* labels YS hemogenic endothelium.

*Lyve1-Cre* Lineage Traces YS Definitive HSPCs but Bypasses the Primitive Erythroid Lineage {#S5}
-------------------------------------------------------------------------------------------

We next interrogated the contribution of LYVE1 lineage cells to the different hematopoietic compartments. *Lyve1-Cre* was crossed with a *R26-stop-YFP* strain, where deletion of the transcriptional stop preceding the YFP sequence in the *Rosa26* locus leads to marking of all progenies with YFP ([Figure 3A](#F3){ref-type="fig"}) ([@R11]).

FACS analysis of E8.5 *Lyve1-Cre;YFP* YS showed labeling in one-third of angioblasts, whereas none of the Ter119^+^ primitive erythroid cells were marked ([Figure 3B](#F3){ref-type="fig"}). Likewise, no labeling was observed in Ter119^+^ cells in E9.0 *Lyve1-Cre;YFP* YS, although 90% of erythroid cells were labeled when the YFP reporter strain was crossed with *Tie2*/*Tek-Cre* mouse, in which Cre is activated in hemato-vascular precursors after gastrulation ([Figure 3C](#F3){ref-type="fig"}) ([@R22]). 100% labeling was observed with the germ-cell-specific *Vasa-Cre* mouse, in which Cre is active during fertilization, enabling Cre recombination in all cells of the conceptus (data not shown) ([@R13]). Hence, using two different Cre lines, we verified that the absence of YFP signal in *Lyve1-Cre;YFP* E9.0 primitive erythroid cells was not explained by silencing of the *Rosa26* locus. Later in development, however, *Lyve1-Cre* tracing of primitive erythroid cells could not be tracked because reporter expression from the *Rosa26* locus was silenced as the primitive erythroid cells matured, irrespective of the Cre line used (data not shown).

Lack of *Lyve1-Cre* labeling in primitive erythroid cells was confirmed by analyzing E9.5 *Lyve1-Cre;Rosa*^*mT*/*mG*^ concepti. Although many CD43^+^ hematopoietic cells in YS had switched from tdTomato to GFP expression, CD71^+^Ter119^+^ primitive erythroid cells retained tdTomato expression ([Figure S2A](#SD1){ref-type="supplementary-material"}), documenting absent *Lyve1-Cre* marking, despite intact activity of the *Rosa26* locus. These data confirm that the primitive erythroid lineage does not originate from LYVE1-expressing hemogenic endothelium.

In contrast to the unlabeled primitive erythroid cells, 69.7% ± 14.8% SD of CD41^mid^cKit^+^ HSPCs in E9.5 *Lyve1-Cre;YFP* YS was marked by YFP ([Figures 3D](#F3){ref-type="fig"} and [3G](#F3){ref-type="fig"}). These data imply that *Lyve1-Cre* marks the stage when the precursors generating YS definitive hemogenic endothelium and HSPCs have separated from the primitive erythroid lineage.

*Lyve1-Cre* Labels a Subset of Fetal and Adult HSCs {#S6}
---------------------------------------------------

To investigate whether *Lyve1-Cre* marking is restricted to EMPs or includes HSCs, we assessed the contribution of lineage-traced cells to fetal and adult HSCs. At E13.5, when the FL HSC compartment has become established and is rapidly expanding, 38.9% ± 11.6% SD of the LSK CD150^+^ HSCs were YFP marked ([Figures 3E](#F3){ref-type="fig"} and [3G](#F3){ref-type="fig"}). In the adult, comparable fractions of YFP labeling were found among LSK CD150^+^ HSCs (37.4% ± 11.1% SD) and Mac1^+^Gr1^+^ myeloid cells (38.2% ± 6.0% SD) in the bone marrow (BM) and CD4^+^CD8^+^ T lymphocytes (39.4% ± 3.5% SD) in the thymus ([Figures 3F](#F3){ref-type="fig"} and [3G](#F3){ref-type="fig"}). The uniform degree of post-natal *Lyve1-Cre* marking in all major lineages is in stark contrast to the absent or low expression of LYVE1 protein in HSCs or in cells committed to the different hematopoietic lineages ([Figure S2B](#SD1){ref-type="supplementary-material"}). These data establish that more than one-third of long-term repopulating HSCs derive from the *Lyve1-Cre* lineage, and that they were labeled during embryonic development.

YS Is the Primary Source of *Lyve1-Cre* Lineage-Derived HSPCs at Mid-gestation {#S7}
------------------------------------------------------------------------------

Although the YS was the only hemogenic organ that showed extensive *Lyve1-Cre* labeling of endothelium during HSPC emergence ([Figure 2F](#F2){ref-type="fig"}), the PL ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}) and EM (data not shown) also harbored CD41^mid^cKit^+^ HSPCs with reporter expression. To examine how circulating cells contribute to the HSPC census in each hemogenic organ, YFP fluorescence was examined in blood cells of heartbeat-deficient *Ncx1*^−/−^ concepti. Although the YS maintained the richly labeled HSPC pool (79% ± 2.8% SD), the absence of circulation in *Ncx1*^−/−^ mutants depleted YFP^+^ labeled HSPCs from the PL ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}). The CD16/32^+^ EMP subset in *Ncx1*^−/−^ mutants also showed a similar redistribution of YFP^+^ fractions ([Figure S2C](#SD1){ref-type="supplementary-material"}). These data suggested that the YS is the main source of *Lyve1-Cre-line-*age-traced HSPCs and EMPs at mid-gestation. Due to the severely defective generation of HSPCs in the *Ncx1*^−/−^ mutant embryos, labeling of HSPCs generated in this organ could not be reliably assessed.

To target the hematopoietic cells derived from the LYVE1 lineage, *Lyve1-Cre* was used to delete the Runt-related transcription factor 1 *(Runx1)* gene, which is required for the generation of EMPs and HSCs. Comparison of *Lyve1-Cre;Runx1*^*fl*/−^ concepti to control tissues at E9.5 showed near depletion of CD41^mid^ckit^+^ HSPCs in the conditional knockout YS. Both the PL and EM showed a partial reduction in their HSPC populations, likely reflecting the lack of migration of *Lyve1-Cre*-depleted HSPCs from the YS. The HSPC populations observed in the PL and EM likely represent the HSPCs generated in situ, which were unaffected by *Lyve1-Cre* mediated *Runx1* deletion ([Figure 3J](#F3){ref-type="fig"}). A parallel defect in myelo-erythroid colony formation was evident in *Lyve1-Cre;Runx1*^*fl*/−^ YS ([Figure 3K](#F3){ref-type="fig"}). As expected from the known function of Runx1 in hemogenic endothelium ([@R6]), genotyping of YS colonies confirmed that only rare cells that had escaped *Lyve1-Cre*-mediated *Runx1* deletion formed colonies ([Figure 3L](#F3){ref-type="fig"}). These genetic labeling and gene ablation data verified that YS HSPCs are efficiently targeted by *Lyve1-Cre*, whereas the PL and EM harbor native HSPCs that do not originate from the LYVE1 lineage.

*Lyve1-Cre* Lineage Tracing Identifies a Temporal Switch in the Precursors Responsible for FL Erythropoiesis {#S8}
------------------------------------------------------------------------------------------------------------

To investigate the contribution of *Lyve1-Cre* lineage cells to FL hematopoiesis, we assessed the fraction of lineage-traced cells in different hematopoietic populations from mid to late gestation. *Lyve1-Cre* marking in the FL Lin^−^cKit^+^CD34^+^Sca1^+^ HSC compartment peaked at E11.5 (61.3% ± 17.8% SD), when the FL seeding by HSCs begins, and leveled to 36.4% ± 11.7% SD at E13.5 and 41.4% ± 10.4% SD at E16.5 ([Figures 4A](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). Of note, CD150, the Slam family marker associated with long-term reconstituting HSCs in mice ([@R20]) was not used in E11.5 FL because it is not reliably expressed in HSCs during early FL colonization ([@R28]). However, incorporating CD150 expression to further characterize HSCs at E13.5 did not change their fraction of *Lyve1-Cre* marking (data not shown). These data suggest that LYVE1-lineage cells are major contributors to initially colonize the FL HSC compartment, whereas by E13.5, non-lineage-traced HSCs co-seed the FL. The uniform degree of HSC marking from E13.5 to adult implies that the respective contributions of *Lyve1-Cre* labeled and non-labeled HSCs to the HSC pool remains stable after the FL HSC compartment has been established by E13.5.

In addition to serving as a site for HSC expansion, the FL supports definitive erythropoiesis through most of the fetal life. Whereas the primitive erythroid cells differentiate in the YS and undergo maturation in circulation, the progenitors for definitive erythroid cells must transit through the FL to differentiate and enucleate ([@R26]). It has been proposed that the precursors that first colonize the FL and initiate definitive erythropoiesis derive from the YS, but their origin and the duration of their contribution have not been experimentally proven.

FACS analysis of *Lyve1-Cre;YFP* FL at E11.5 revealed that it contained CD71^+^Ter119^−^ pro-erythroblasts (ProE) and ckit^+^ CD34^−^ hematopoietic progenitor cells (HPCs) with extensive YFP marking (76.7% ± 4.7% SD and 79.3% ± 3.0% SD, respectively) ([Figures 4A](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}), which was comparable to the level measured in E9.5 YS CD41^mid^cKit^+^ HSPCs ([Figures 3D](#F3){ref-type="fig"} and [3G](#F3){ref-type="fig"}). This suggests that the YS supplies the precursors that first colonize the FL to initiate definitive erythropoiesis. By E13.5, 63.2% ± 8.7% SD of the ProE and 51.0% ± 5.5% SD of FL HPCs derived from the LYVE1 lineage ([Figures 4B](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). These compartments displayed significantly higher marking than the Lin^−^Sca1^+^cKit^+^CD34^+^ HSC subset (36.4% ± 11.7% SD), implicating that the progenitors responsible for FL-definitive erythropoiesis derive from a different source than most HSCs at this stage. By E16.5, the ProE- and HSC-enriched populations exhibited similar degrees of *Lyve1-Cre* marking (41.2% ± 8.1% SD and 41.4% ± 10.3% SD, respectively), suggesting that by late gestation, HSCs become responsible for FL erythropoiesis ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}).

*Lyve1-Cre*-Mediated Deletion of *Scl*/*Tal1* Targets Early FL Definitive Erythropoiesis but Spares the Primitive Erythroid Lineage {#S9}
-----------------------------------------------------------------------------------------------------------------------------------

To confirm that the *Lyve1-Cre* strain can be used to manipulate early definitive erythropoiesis without affecting primitive erythropoiesis, we created a *Lyve1-Cre*-mediated conditional knockout of the transcription factor SCL. Although SCL is essential for the specification of hemogenic endothelium ([@R43]; [@R53]), it is dispensable for HSC maintenance ([@R31]) because of redundancy with LYL1 ([@R51]). Because SCL is required for the terminal differentiation of all erythroid cells, inactivation of *Scl* by *Tie2-Cre* results in defects in both primitive and definitive erythropoiesis ([@R47]). As previously reported, May-Grunwald Giemsa stain of E12.5 peripheral blood from *Tie2-Cre;Scl*^*fl*/−^ mutants displayed abnormal primitive erythroid cells that were mitotic, binucleated, or had a larger nucleus-to-cytoplasm ratio than control littermates, implying defective maturation ([Figure 5A](#F5){ref-type="fig"}). Furthermore, 2-hr 5-Bromo-2'-deoxyuridine (BrDU) pulse analysis showed a high fraction of mutant erythroid cells undergoing DNA replication ([Figure 5B](#F5){ref-type="fig"}). In contrast, when *Scl* was excised in *Lyve1-Cre*-expressing cells, the primitive erythroid cells did not show abnormal morphology or proliferation, indicating that they had been spared from *Scl* inactivation ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}).

Both *Tie2-Cre;Scl*^*fl*/−^ and *Lyve1-Cre;Scl*^*fl*/−^ E12.5 fetal livers showed an increase in the CD71^+^Ter119^−^ ProE fraction ([Figures 5C](#F5){ref-type="fig"} and [5E](#F5){ref-type="fig"}), consistent with delayed maturation reported in *Scl*-deficient definitive erythroid cells ([@R31]; [@R47]). This defect was ameliorated by E13.5 ([Figures 5D](#F5){ref-type="fig"} and [5E](#F5){ref-type="fig"}), likely due to replenishment of the FL ProE pool by a new source of unaffected precursors. These data verify that *Lyve1-Cre* deletes *Scl* specifically from the transient-definitive, but not primitive erythroid cells, enabling studies that address the impact of the different erythroid waves on embryonic development.

DISCUSSION {#S10}
==========

The challenge of tracking the origin and contribution of the different waves of developmental hematopoiesis in vivo has limited the understanding of their unique roles in the embryo and adult. We report that LYVE1 expression and lineage tracing can be used to specifically examine the definitive hematopoiesis originating from the YS and/or vitelline vessels without targeting the primitive erythroid lineage or the majority of the HSC compartment generated elsewhere in the conceptus.

LYVE1 protein expression and *Lyve1-Cre* fate mapping distinguished endothelial cells from the YS and vitelline vessels from those from other hemogenic organs at the developmental window when HSPCs emerge. Although LYVE1^+^ EMPs and HSPCs could be detected in all hemogenic organs in concepti with normal circulation, analysis of heartbeat-deficient *Ncx1*^−/−^ concepti implied that the YS is the main source of LYVE1^+^ HSPC and EMPs. These data propose that some, if not all, HSCs of *Lyve1-Cre* lineage, which constitute more than one-third of the fetal and the adult HSC pools, originate from the YS and/or vitelline vessels. However, because LYVE1 protein expression appears in PL vasculature at late gestation and a low level of *Lyve1-Cre* marking is noted in PL and EM endothelium at mid-gestation, our data do not exclude the possibility that other hemogenic organs may also contribute to the LYVE1-lineage-traced HSC pool. The *Ncx1*^−/−^ model cannot be used to assess adult-repo-pulating HSC activity of *Lyve1-Cre*-marked cells because these embryos die by E10.0--before transplantable HSCs can be har-vested--and because heartbeat is critical for proper HSC development ([@R37]). Hence, the question of whether all or most of the 35%−40% *Lyve1-Cre*-marked fetal and adult HSPCs arise from the YS and/or vitelline vessels requires further studies using different experimental systems. Nevertheless, because the YS generates predominantly *Lyve1-Cre*-marked HSPCs, while the PL and the EM produce mostly unmarked ones, our data propose that HSCs from multiple anatomical sites contribute to adult hematopoiesis. How these different lineages of HSCs contribute to the various hematopoietic subsets in the adult can now be approached experimentally in vivo using the *Lyve1-Cre* model. This is important because HSCs are heterogeneous and can show cell intrinsic biases to different hematopoietic lineages in an age-dependent manner ([@R2]; [@R3]; [@R41]; [@R50]; [@R57]).

Our data document that the LYVE1^+^ endothelium in the YS does not give rise to primitive erythroid cells. The absence of LYVE1 protein expression and marking in the primitive erythroid cell contrasts with the abundant protein expression and marking in YS definitive HSPC. These data imply that these two hematopoietic lineages have separated from a common mesodermal precursor before *Lyve1-Cre* becomes active. The YS thus gives rise to at least two lineages of erythroid cells that originate from distinct precursors. The *Lyve1-Cre* lineage trace may thus provide clarity to studies that challenged the "lineage switch model" by reporting that the types of globins expressed in primitive or definitive erythroid lineages are not mutually exclusive because the cells undergo "maturational globin switch" during erythroid differentiation ([@R21]; [@R26]; [@R40]; [@R44]).

LYVE1 expression and lineage tracing offer a powerful tool to separate primitive erythroid lineage from early fetal definitive erythropoiesis. The defects in both primitive and definitive erythroid cell differentiation caused by the conditional deletion of *Scl* by *Tie2-Cre* ([@R47]) were uncoupled using *Lyve1-Cre*, which disrupted only the early FL definitive erythropoiesis. Selective inactivation of key hematopoietic regulators in *Lyve1-Cre* progenies makes it possible to study the requirement of such factors in early FL erythropoiesis without the confounding effects of early embryonic lethality, as in *Scl* null embryos ([@R43]; [@R49]), or primitive erythroid defects, as in *Tie2-Cre;Scl*^*fl*/−^ concepti.

The *Lyve1-Cre* model also provides in vivo evidence that the earliest progenitors seeding and initiating FL erythropoiesis are products of a distinct lineage that likely emerges from the YS. However, the deletion of *Scl* in LYVE1-lineage cells causes only a temporary effect on FL erythropoiesis, possibly because progenitors from other sources that were spared from *Lyve1-Cre* deletion also converge to the FL and replenish the initially attenuated erythroid compartment. Future studies will inform whether the erythroid progenitors or HSCs belonging to the LYVE1 lineage exhibit different properties than those arising from non-LYVE1-lineage precursors.

LYVE1 is expressed abundantly in lymphatic vessels and lymph node sinus endothelial cells, but its expression has also been described in other cell types, such as liver blood sinusoids and tissue macrophages ([@R34]; [@R42]; [@R48]). In the YS, LYVE1 expression is not related to lymphatic identity because the YS does not contain lymphatic vasculature ([@R1]; [@R16]). It is unknown how the YS- and vitelline-vessel-restricted expression pattern of LYVE1 among hemogenic vessels is established, and whether this is intrinsically regulated or if it involves signals from the microenvironment. It will be interesting to determine whether LYVE1 expression is also enriched in YS and vitelline vessels and HSPCs during human development, and how the expression pattern is preserved during ESC differentiation.

The functional significance of LYVE1 expression in YS endothelial or hematopoietic cells is unknown. Although it was suggested to serve in cell adhesion/transmigration and as a scavenger for hyaluronan turnover, mouse knockout studies in either 129/C57BL/6 or C57BL/6 background were unable to demonstrate a critical function for LYVE1 in these processes or in embryonic development in general ([@R12]). The Cre cassette was inserted into the 3′UTR of the endogenous *Lyve1* locus, avoiding disruption in the LYVE1 protein. Hence, our model cannot be used to answer whether loss of LYVE1 causes subtle effects in hematopoiesis that would be observed upon more detailed examination or backcrossing to other genetic backgrounds. However, because of the hematopoietic wave- and tissue-restricted expression of LYVE1, the *Lyve1-Cre* model can be exploited to uncover new functions for the different blood progenitor lineages and HSC sources during developmental and adult hematopoiesis.

EXPERIMENTAL PROCEDURES {#S11}
=======================

Mouse Models {#S12}
------------

*Lyve1-eGFP-hCre* knockin mice (C57BL/6) ([@R42]) were crossed with two reporter lines: (1) *R26-YFP* carrying a floxed transcriptional stop upstream of the YFP in Rosa26 locus ([@R52]), and (2) double-fluorescent reporter (*Rosa*^*mT*/*mG*^), where cells express Tomato constitutively but switch to GFP upon excision ([@R36]). Whereas YFP or GFP fluorescence rendered from crossing with the reporter lines could clearly highlight the Cre-excised cells, eGFP from *Lyve1-eGFP-hCre* alone could not be discerned by fluorescence microscopy, as previously reported ([@R42]). FACS analysis confirmed the low eGFP signal from *Lyve1-eGFP-hCre*, which did not overlap with the intense YFP or GFP signal. Hence, for simplicity, the *Lyve1-eGFP-hCre* is referred as *Lyve1-Cre*. To label the entire hemato-vascular compartment, *Tie-2*/*Tek-Cre* mice ([@R22]) were bred with the *R26-YFP* line. To label all cells of the conceptus, the germ-cell-specific *Vasa-Cre* was crossed with the R26-YFP line. *Lyve1-Cre;YFP* mice were further crossed with *Ncx1*^+/−^ mice ([@R23]) to generate *Ncx1*^−/−^ mutants that underwent *Lyve1-Cre* labeling and lacked circulation. Although some contaminating embryonic red blood cells (RBCs) could occasionally be found in the embryo proper of *Ncx1*^−/−^ concepti, only embryos with less than 5% RBC contamination were used in the analysis. *Lyve1-Cre* was also bred with *Runx1*^*fl*/−^ ([@R17]; [@R54]) and *Scl*^*fl*/−^ ([@R31]; [@R49]). Embryos were not separated based on sex, and both female and male embryos were studied. Mice were maintained according to protocols of Animal Research Committee at the University of California, Los Angeles, and the University of California, Irvine, who approved these studies.

See the [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"} for preparation of tissue sections, immunostaining, flow cytometry, clonogenic progenitor assay, cytospin, cell proliferation assay, and statistical analysis.
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![LYVE1 Protein Is Expressed in Yolk Sac Endothelium and Hematopoietic Stem and Progenitor Cells\
(A) LYVE1 protein is detected by IF in E10.5 YS, vitelline vessels (VVs), and the cardinal vein (CV), but is absent from the PL, umbilical vessels (UVs), and DA. Representative images from three independent experiments. Scale bar, 100 μm.\
(B) IF staining shows co-localization of LYVE1 in E9.5 YS CD31^+^ endothelium. Representative image from three independent experiments. Scale bar, 100 μm.\
(C) FACS analysis of CD31^+^CD41^−^Ter119^−^ endothelium in YS, PL, and caudal half of the EM of one representative E9.5 conceptus. Corresponding histograms of LYVE1^+^ endothelial cells show robust LYVE1 expression in YS endothelium only. Data from n = 11 from three independent experiments are represented as mean ± SD; \*\*\*P ≤ 0.001.\
(D) LYVE1 protein is not discernible by IF in Ter119^+^ primitive erythroid cells in E10.5 YS. Representative image from two independent experiments is shown. Scale bar, 50 μm.\
(E) Representative FACS plots indicate that Ter119^+^ primitive erythroid cells (pRBCs) do not express LYVE1 in E9.5 YS or E11.0 peripheral blood (PB).\
(F) IF staining of E9.5 YS shows co-expression of LYVE1 protein with HSPC marker CD41. Representative image from three independent experiments is shown. Scale bar, 50 μm.\
(G) Representative FACS plots show LYVE1 expression in CD41^mid^cKit^+^Ter119^−^ HSPCs and its subset, CD16/32^+^ EMPs in E9.25 YS.\
(H) Representative FACS plots of E13.5 FL document minimal LYVE1 expression in Lin^−^Sca1^+^cKit^+^ CD150^+^ HSC compartment.\
(I) LYVE1 expression is prominent in mid-gestation YS HSPCs and EMPs. Data from n = 8, three independent experiments for YS pRBC; n = 28,10 independent experiments for YS HSPC; n = 8, three independent experiments for YS EMP; and n = 6, two independent experiments for FL HSC subset are shown as mean ± SD.\
(J) Representative FACS plots of hemogenic tissues in *Ncx1*^−/−^ E9.5 concepti demonstrate the enrichment of LYVE1-expressing CD41^mid^cKit^+^Ter119^−^ HSPCs in the YS.\
(K) Significantly higher HSPC fraction in the YS than in the PL or EM expresses LYVE1 protein in *Ncx1*^−/−^ concepti. Quantification of n = 23 for control and n = 11 for *Ncx1*^−/−^ from five independent experiments is represented as mean ± SD. p values refer to the difference between LYVE1^+^ fractions; \*\*\*\*P ≤ 0.0001.\
See also [Figure S1](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1029829-f0002){#F1}

![*Lyve1-Cre* Labels Yolk Sac Endothelium and Vitelline Vessels\
(A) Schematic of mouse model for tracing *Lyve1-Cre* lineage cells using the *Rosa*^*mT*/*mG*^ reporter line.\
(B) Brightfield and whole mount fluorescence microscopy images of *Lyve1-Cre;mTmG* E8.5 concepti show the replacement of Tomato (red) by GFP (green) expression in the YS. Representative image from n = 8 concepti from two independent experiments. Scale bar, 500 μm.\
(C) Brightfield and whole mount fluorescence microscopy images of YS, EM, and PL at E10.5. (i) shows GFP expression in the fetal liver (FL; dashed outline) and the vitelline vessels (VV; green arrow). (ii) shows intact Tomato activity in PL and umbilical vessels (UV; red arrow) and in the dorsal aorta (DA). GFP^+^ hematopoietic cells (green arrowheads) are found in PL vasculature (ii), heart (H) and limb bud (LB; dashed outline) (iii), and YS (iv). GFP expression is prominent throughout YS vasculature (iv). Representative image of n = 18 embryos from three independent experiments. Scale bar, 500 μm.\
(D) At E10.5, GFP labeling is widespread in YS and VV CD31^+^ endothelium, but minimal in the DA. Representative image from two independent experiments. Scale bar, 250 μm.\
(E) Representative FACS plots of GFP labeling of VE-Cad^+^CD31^+^ endothelial cells in E9.5 YS, PL, and caudal half of the EM.\
(F) Bar graphs of endothelial cells show robust *Lyve1-Cre* lineage tracing in YS at E9.5--E11.5. EM refers to the caudal half of the embryo at E9.5 and the aorta-gonad-mesonephros region at E10.5 and E11.5. Data are from pools of embryos from three (E9.5), seven (E10.5), and three (E11.5) independent experiments and are represented as mean ± SD.\
See also [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1029829-f0003){#F2}

![*Lyve1-Cre* Targets Yolk-Sac-Definitive Hematopoiesis\
(A) Schematic of mouse model for tracing *Lyve1-Cre*-marked cells using the *R26-stop-YFP* reporter.\
(B) Representative FACS plots of E8.5 conceptus show *Lyve1-Cre;YFP* labeling in Tie2^+^CD31^+^ angioblasts, but not in Ter119^+^ primitive erythroid cells (pRBCs).\
(C) Representative FACS plots of E9.0 YS demonstrate labeling of Ter119^+^ pRBC by *Tie2-Cre*, but not by *Lyve1-Cre*.\
(D) Representative FACS plots of E9.5 YS demonstrate labeling of YS CD41^mid^cKit^+^Ter119^−^ HSPCs and CD16/32^+^ EMPs by *Lyve1-Cre*.\
(E and F) Representative FACS plots display similar YFP marking in the Lin^−^Sca1^+^cKit^+^CD150^+^ HSC of E13.5 FL (E) and 8-month-old adult BM (F).\
(G) Quantification shows a contrast of YFP marking between pRBCs (n = 4, two independent experiments) and YS HSPCs (n = 15, 7 independent experiments). *Lyve1-Cre* marking in E13.5 FL Lin^−^Sca1^+^cKit^+^CD150^+^ HSCs (n = 15, 4 independent experiments) is similar to 8-month-old adult BM HSCs, BM Mac1^+^Gr1^+^ myeloid cells (n = 8, two independent experiments), and thymus CD4^+^CD8^+^ T lymphocytes (n = 7, two experiments). No comparison of marking between populations yielded statistical difference. Data are represented as mean ± SD.\
(H) Representative FACS plots of E9.5 *Lyve1-Cre;YFP Ncx1*^−/−^ concepti show preservation of YFP^+^ HSPCs in the YS but near depletion in the PL when blood circulation is absent.\
(I) Quantification of YFP^+^ fraction in HSPCs of E9.5 *Ncx1*^−/−^ concepti with impaired circulation. Data from n = 16 for *Ncx1*^*CTR*^ and n = 5 for *Ncx1*^−/−^ from three independent experiments are represented as mean ± SD; \*\*p value of the difference in YFP^+^ fractions at ≤ 0.01.\
(J) Representative FACS plots and quantification of HSPCs in hemogenic organs of E9.5 *LYve1-Cre;Runx1*^*fl*/−^ tissues show depletion of HSPCs from the YS upon conditional deletion of *Runx1* in LYVE1 lineage cells. The loss in HSPCs is partial in the PL and insignificant in the EM. Data from n = 4 for mutants and n = 9 for controls from three independent experiments are represented as mean ± SD. p values are shown as ns if \> 0.05; \*P ≤ 0.05; \*\*P ≤ 0.01.\
(K) Quantification of myelo-erythroid colonies per embryo equivalent (ee) from each organ. Data from n = 4 for mutants and n = 3 for controls from two independent experiments are represented as mean ± SD.\
(L) Genotyping of *Runx1* alleles in representative colonies.\
See also [Figure S2](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1029829-f0004){#F3}

![Progenitors of *Lyve1-Cre* Lineage Initiate Fetal Liver Hematopoiesis\
(A) Representative FACS plots of *Lyve1-Cre* marking in hematopoietic subpopulations in one representative E11.5 FL: Ter119^−^ CD71^+^ proerythroblasts (ProEs), Ter119^−^cKit^+^ HPCs, and Ter119^−^CD34^+^cKit^+^Sca1^+^ HSPCs.\
(B) Representative FACS plots of FL subsets at E13.5.\
(C) Representative FACS plots of FL subsets at E16.5.\
(D) Comparative analysis of E11.5, E13.5, and E16.5 FL illustrates a shift in hematopoietic populations derived from the *Lyve1-Cre* lineage. Data from n = 9, three independent experiments for E11.5, n = 18, three independent experiments for E13.5, and n = 13, two independent experiments for E16.5, are represented as mean ± SD. p values are shown as ns if \> 0.05; \*P ≤ 0.05; \*\*P ≤ 0.01; \*\*\*P ≤ 0.001; \*\*\*\*P ≤ 0.0001.\
See also [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1029829-f0005){#F4}

![*Lyve1-Cre* Targets Early Fetal Liver Definitive Hematopoiesis\
(A) May-Grunwald Giemsa stain of E12.5 peripheral blood (PB) shows primitive erythroid defects in *Tie2-Cre;Scl*^*fl*/−^ blood cells (arrows), but not in *Lyve1-Cre;Scl*^*fl*/−^ blood. Representative images from three independent experiments are shown.\
(B) Representative FACS plots of BrDU staining of E12.5 PB illustrate excessive proliferative activity in *Tie2-Cre;Scl*^*fl*/−^ primitive erythroid cells, but not in *Lyve1-Cre;Scl*^*fl*/−^ cells. Bar graphs from n = 22 controls and n = 4 knockouts from three independent *Tie2-Cre;Scl*^*fl*/−^ experiments and n = 6 controls and n = 3 knockouts from two independent *Lyve1-Cre;Scl*^*fl*/−^ experiments are shown as mean ± SD.\
(C) E12.5 FLs from both *Tie2-Cre;Scl*^*fl*/−^ (upper panel) and *Lyve1-Cre;Scl*^*fl*/−^ (lower panel) embryos exhibit accumulation of proerythroblasts (ProEs).\
(D) At E13.5, the defect in ProE fraction in *Lyve1-Cre;Scl*^*fl*/−^ FL has corrected.\
(E) Quantification of ProE fractions in E12.5 and E13.5 FL. Data from n = 2 (E12.5 *Tie2-Cre;Scl*^*fl*/−^) and n = 6 (control), n = 3 (E12.5 *Lyve1-Cre;Scl*^*fl*/−^) and n = 7 (control), and n = 4 (E13.5 *Lyve1-Cre; Scl*^*fl*/−^) and n = 14 (control) from two independent experiments for each genotype and age are shown as mean ± SD.\
See also [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1029829-f0006){#F5}

###### Highlights

-   LYVE1 is expressed in yolk sac endothelium and hematopoietic stem and progenitor cells

-   *Lyve1-Cre* marks yolk sac definitive hematopoiesis but bypasses primitive erythropoiesis

-   LYVE1 lineage cells initiate fetal liver definitive erythropoiesis

-   A subset of fetal and adult hematopoietic stem cells are derived from the LYVE1 lineage
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